Table 1.

Characteristics of study patients.

Age	Gender	Adverse Allopurinol Event	Febuxostat Starting Dose (mg)	Febuxostat Current Dose, mg	SUA Initial, mg/dl	SUA Post, mg/dl	Percentage SUA Reduction	Duration on Drug (mo)	Estimated Cr CI (ml/min)
85	F	Exfoliative erythroderma requiring hospitalization	40	0	10.9	Unknown	xxx	0.25	33.7
52	F	Full body rash with desquamation	40	80	14	9.5	32	15	60.0
74	F	Dyspnea, likely acute renal failure	40	40	11.3	6.9	39	12	56.2
83	M	Full body rash	40	80	9.8	4.7	52	13	52.3
66	M	Rash	40	60	10.2	4.6	55	12	65.1
70	M	Acute renal failure, eosinophilia and vasculitis on bx	20	20	11	5.9	46	7	27.4
71	M	Desquamating skin rash	40	40	9.9	Unknown	xxx	1.5	50.6
60	M	Desquamating skin rash of mouth	40	80	13.7	5.6	59	9	91.2
75	F	Rash	40	40	10.3	4.8	53	3	18.3
71	M	Severe cutaneous reaction	40	100	8.8	5	43	13	57.6
62	M	Diffuse rash	40	40	8.7	5.7	34	16	29.2
80	F	Diffuse cutaneous reaction on worsening chronic kidney diagnosis	40	40	10.2	4.9	52	13	14.7
75	M	Rash and eosinophilia	40	40	7.5	5.6	25	6	81.0